— Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported earnings of 69 cents per share during fiscal year 2019, compared to a loss of 65 cents per share a year ago.
— For the full year, revenue rose to $168.7 million, vs. $16.1 million last year.
— During Q4, the company started dosing patients in an adaptive design Phase 2/3 trial, called SEQUOIA, with the potential to serve as a pivotal registrational study of ARO-AAT.
— ARWR shares have more-than-quadrupled since the beginning of this year.
Most Popular
NKE Earnings: Nike reports lower sales for Q3 2025
NIKE, Inc. (NYSE: NKE) has reported a decline in earnings for the third quarter of 2025, hurt by a slowdown in sales across all major markets and operating segments. The
NIO Infographic: A snapshot of Nio’s Q4 2024 earnings report
China-based electric car maker NIO Inc. (NYSE: NIO) on Friday reported a net loss for the fourth quarter of 2024. Revenues increased by double-digits during the three months. Total revenues
Infographic: How FedEx (FDX) performed in Q3 2025
FedEx Corp. (NYSE: FDX) reported revenue of $22.2 billion for the third quarter of 2025, up 2% compared to the same quarter a year ago. GAAP net income was $909
